GlassScriptPhysician profile
Mary Young Lowry
NPI 1285952465
$4,799.56
in general payments reported to CMS, 2019-2025
25 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $183 · 2021: $308 · 2022: $443 · 2023: $186 · 2024: $2,849 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,412 · Food and Beverage: $990 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,412.00 |
| Food and Beverage | $990.02 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $2,564.22 | 2022-2024 | Dupixent |
| Abbvie INC. | $618.87 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.31 | 2019-2024 | Xifaxan |
| Qol Medical, LLC | $238.80 | 2022-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $184.64 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $168.14 | 2024-2025 | Tremfya |
| Genzyme Corporation | $150.73 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $81.98 | 2019 | |
| Phathom Pharmaceuticals, INC. | $81.06 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $71.32 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $55.57 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $49.69 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $47.39 | 2024-2025 | |
| Celgene Corporation | $39.57 | 2024 | Zeposia |
| Redhill Biopharma INC. | $23.40 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $18.26 | 2022 | |
| Pharmacosmos Therapeutics INC. | $17.92 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.12 | 2022 | |
| Novo Nordisk INC | $16.60 | 2025 | Saxenda, Wegovy |
| Ironwood Pharmaceuticals, INC | $15.98 | 2024 | |
| Travere Therapeutics, INC. | $14.80 | 2019 | |
| Pfizer INC. | $14.33 | 2019 | |
| Neuraxis, INC. | $13.86 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$39,706.98 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Young Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.